Changes in Weight, Body Composition and Cardiac Risk After Discontinuing Abacavir Treatment in HIV-infected Individuals

NCT04904406 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

81

Enrollment

OTHER

Sponsor class

Conditions

Hiv
HIV Infections
HIV Cardiomyopathy
Weight Change, Body
HIV Lipodystrophy
Cardiovascular Diseases

Interventions

DRUG: Dolutegravir / Lamivudine Oral Tablet

Sponsor

Thomas Benfield